![](https://i.imgur.com/CLvY2jA.png")
The treatment contains two mAbs: casirivimab and imdevimab. They are designed to stop the coronavirus attaching to ACE2, a receptor found on the surface of human cells in the respiratory tract.
Two Vectors
One of the mAbs is derived from a Covid-fighting immune cell taken from a human survivor of the disease.
The other was produced in a mouse genetically modified to have a human immune system.
The advantage of combining the two is that they target two different parts of the spike protein, many of which protrude from the coronavirus – these are what it uses to bind with ACE2.
Using both reduces the chance of the virus escaping from the immune system.
https://scroll.in/article/1004035/explai...and-now-uk
Two Vectors
One of the mAbs is derived from a Covid-fighting immune cell taken from a human survivor of the disease.
The other was produced in a mouse genetically modified to have a human immune system.
The advantage of combining the two is that they target two different parts of the spike protein, many of which protrude from the coronavirus – these are what it uses to bind with ACE2.
Using both reduces the chance of the virus escaping from the immune system.
https://scroll.in/article/1004035/explai...and-now-uk
